Vasudha Tandon

发表

Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo

Albert C. Chen, M. Pirrung, R. Sah, 2021, bioRxiv.

Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression

Edwin F. Juarez, J. Mesirov, J. Dixon, 2019, Proceedings of the National Academy of Sciences.

Synthesis of N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKBβ/AKT2 inhibitory and in vitro anti-glioma activity

Yanlong Gu, H. Patel, Sourav Banerjee, 2022, Annals of medicine.

Emerging roles of DYRK2 in cancer

L. de la Vega, Sourav Banerjee, Vasudha Tandon, 2020, The Journal of biological chemistry.

Ca2+-dependent liquid-liquid phase separation underlies intracellular Ca2+ stores

A. Newton, C. Worby, J. Dixon, 2021, bioRxiv.

Glasgow Neuro Society 2021 Conference Proceedings

G. Kontorinis, Mark Hughes, Mohammad Ashraf, 2022, Surgical neurology international.

Dual inhibition of HSF1 and DYRK2 impedes cancer progression

J. Quinn, J. Edwards, R. Moreno, 2023, Bioscience reports.

AI is a viable alternative to high throughput screening: a 318-target study

Eva M García-Cuesta, Frederick S. Vizeacoumar, Stephen J. Capuzzi, 2024, Scientific reports.

One-pot synthesis of tetrahydropyrimidinecarboxamides enabling in vitro anticancer activity: a combinative study with clinically relevant brain-penetrant drugs

Vasudha Tandon, Ruturajsinh M. Vala, Dipti B Upadhyay, 2024, RSC advances.